Investigating the role of Sirt1-modulated oxidative stress in relation to benign paroxysmal positional vertigo and Parkinson's disease

Neurobiology of Aging

Volumn 36, Issue 9, 2015, Pages 2607-2616

  Tsai, Kun Ling ^a   Cheng, Yuan Yang ^b,c   Leu, Hsin Bang ^b,d   Lee, Yi Yen ^b,d   Chen, Tzeng Ji ^b,d   Liu, Ding Hao ^b,d   Kao, Chung Lan ^b,d  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Benign paroxysmal positional vertigo; Oxidative stress; Parkinson's disease; SIRT1

Indexed keywords

AMANTADINE; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CARBIDOPA; LEVODOPA; OXIDOPAMINE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; SIRTUIN 1; ADRENERGIC RECEPTOR STIMULATING AGENT; CHROMONE DERIVATIVE; ERYVARIN F; NERVE GROWTH FACTOR; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; SIRT1 PROTEIN, HUMAN; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSCRIPTION FACTOR;

ADULT; ANIMAL CELL; ARTICLE; BENIGN PAROXYSMAL POSITIONAL VERTIGO; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MODEL; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HEAD INJURY; HIGH RISK POPULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PC12 CELL LINE; PRIORITY JOURNAL; RAT; AGE; AGED; ANIMAL; BLOOD; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MITOCHONDRIAL MEMBRANE POTENTIAL;

ADRENERGIC AGENTS; ADULT; AGE FACTORS; AGED; ANIMALS; BCL-2-ASSOCIATED X PROTEIN; BENIGN PAROXYSMAL POSITIONAL VERTIGO; CHROMONES; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MIDDLE AGED; NERVE GROWTH FACTOR; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSON DISEASE; PC12 CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; REACTIVE OXYGEN SPECIES; SIRTUIN 1; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRANSCRIPTION FACTORS;

EID: 84940467197     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.05.012     Document Type: Article

References (54)

1. Aranke S.V., Sethi K.D. Benign paroxysmal positional vertigo in Parkinson's disease. Neurology 2003, 61:1156.
2. Benazzouz A., Mamad O., Abedi P., Bouali-Benazzouz R., Chetrit J. Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson's disease. Front. Aging Neurosci. 2014, 6:87.
3. Blanchet J., Longpre F., Bureau G., Morissette M., DiPaolo T., Bronchti G., Martinoli M.G. Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1243-1250.
4. Bower J.H., Maraganore D.M., Peterson B.J., McDonnell S.K., Ahlskog J.E., Rocca W.A. Head trauma preceding PD: a case-control study. Neurology 2003, 60:1610-1615.
5. Brandt T., Daroff R.B. Physical therapy for benign paroxysmal positional vertigo. Arch. Otolaryngol. 1980, 106:484-485.
6. Camilleri A., Vassallo N. The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease. CNS Neurosci. Ther. 2014, 20:591-602.
7. Canto C., Auwerx J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol. Metabol. 2009, 20:325-331.
8. Chao Y., Wong S.C., Tan E.K. Evidence of inflammatory system involvement in Parkinson's disease. Biomed. Res. Int. 2014, 2014:308654.
9. Cheng Y.Y., Leu H.B., Chen T.J., Chen C.L., Kuo C.H., Lee S.D., Kao C.L. Metformin-inclusive therapy reduces the risk of stroke in patients with diabetes: a 4-year follow-up study. J.stroke Cerebrovasc. Dis. 2014, 23:e99-105.
10. Donmez G., Arun A., Chung C.Y., McLean P.J., Lindquist S., Guarente L. SIRT1 protects against alpha-synuclein aggregation by activating molecular chaperones. J.Neurosci. 2012, 32:124-132.
11. Dragicevic E., Schiemann J., Liss B. Dopamine midbrain neurons in health and Parkinson's disease: emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels. Neuroscience 2015, 284:798-814.
12. Ekstrand M.I., Terzioglu M., Galter D., Zhu S., Hofstetter C., Lindqvist E., Thams S., Bergstrand A., Hansson F.S., Trifunovic A., Hoffer B., Cullheim S., Mohammed A.H., Olson L., Larsson N.G. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1325-1330.
13. Enciu A.M., Gherghiceanu M., Popescu B.O. Triggers and effectors of oxidative stress at blood-brain barrier level: relevance for brain ageing and neurodegeneration. Oxid. Med. Cell. Longev. 2013, 2013:297512.
14. Epley J.M. The canalith repositioning procedure: for treatment of benign paroxysmal positional vertigo. Otolaryngol. Head Neck Surg. 1992, 107:399-404.
15. Epley J.M. Positional vertigo related to semicircular canalithiasis. Otolaryngol. Head Neck Surg. 1995, 112:154-161.
16. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann. N. Y. Acad. Sci. 2003, 991:1-14.
17. Fang F., Chen H., Feldman A.L., Kamel F., Ye W., Wirdefeldt K. Head injury and Parkinson's disease: a population-based study. Mov. Disord. 2012, 27:1632-1635.
18. Feng M., Zhang L., Liu Z., Zhou P., Lu X. The expression and release of Hsp60 in 6-OHDA induced invivo and invitro models of Parkinson's disease. Neurochem. Res. 2013, 38:2180-2189.
19. Finucane D.M., Bossy-Wetzel E., Waterhouse N.J., Cotter T.G., Green D.R. Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J.Biol. Chem. 1999, 274:2225-2233.
20. Froehling D.A., Silverstein M.D., Mohr D.N., Beatty C.W., Offord K.P., Ballard D.J. Benign positional vertigo: incidence and prognosis in a population-based study in Olmsted County, Minnesota. Mayo Clinic Proc. 1991, 66:596-601.
21. Gacek R.R. Pathology of benign paroxysmal positional vertigo revisited. Ann. Otol. Rhinol. Laryngol. 2003, 112:574-582.
22. Gallagher D.A., Schapira A.H. Etiopathogenesis and treatment of Parkinson's disease. Curr. Top. Med. Chem. 2009, 9:860-868.
23. Godbolt A.K., Cancelliere C., Hincapie C.A., Marras C., Boyle E., Kristman V.L., Coronado V.G., Cassidy J.D. Systematic review of the risk of dementia and chronic cognitive impairment after mild traumatic brain injury: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. Arch. Phys. Med. Rehabil. 2014, 95(3 Suppl):S245-S256.
24. Hall S.F., Ruby R.R., McClure J.A. The mechanics of benign paroxysmal vertigo. J.Otolaryngol. 1979, 8:151-158.
25. Hassan W., Silva C.E., Mohammadzai I.U., da Rocha J.B., J L.F. Association of oxidative stress to the genesis of anxiety: implications for possible therapeutic interventions. Curr. Neuropharmacol. 2014, 12:120-139.
26. Jeong H., Cohen D.E., Cui L., Supinski A., Savas J.N., Mazzulli J.R., Yates J.R., Bordone L., Guarente L., Krainc D. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat. Med. 2012, 18:159-165.
27. Jordan J., Cena V., Prehn J.H. Mitochondrial control of neuron death and its role in neurodegenerative disorders. J.Physiol. Biochem. 2003, 59:129-141.
28. Jove M., Portero-Otin M., Naudi A., Ferrer I., Pamplona R. Metabolomics of human brain aging and age-related neurodegenerative diseases. J.Neuropathol. Exp. Neurol. 2014, 73:640-657.
29. Kamat P.K., Kalani A., Kyles P., Tyagi S.C., Tyagi N. Autophagy of mitochondria: a promising therapeutic target for neurodegenerative disease. Cell Biochem. Biophys. 2014, 70:707-719.
30. Kao C.L., Hsieh W.L., Chern C.M., Chen L.K., Lin M.H., Chan R.C. Clinical features of benign paroxysmal positional vertigo (BPPV) in Taiwan: differences between young and senior age groups. Arch. Gerontol. Geriatr. 2009, 49(Suppl 2):S50-S54.
31. Li L., Tan H., Gu Z., Liu Z., Geng Y., Liu Y., Tong H., Tang Y., Qiu J., Su L. Heat stress induces apoptosis through a Ca(2)(+)-mediated mitochondrial apoptotic pathway in human umbilical vein endothelial cells. PLoS One 2014, 9:e111083.
32. Michan S., Li Y., Chou M.M., Parrella E., Ge H., Long J.M., Allard J.S., Lewis K., Miller M., Xu W., Mervis R.F., Chen J., Guerin K.I., Smith L.E., McBurney M.W., Sinclair D.A., Baudry M., de Cabo R., Longo V.D. SIRT1 is essential for normal cognitive function and synaptic plasticity. J.Neurosci. 2010, 30:9695-9707.
33. Mudo G., Makela J., Di Liberto V., Tselykh T.V., Olivieri M., Piepponen P., Eriksson O., Malkia A., Bonomo A., Kairisalo M., Aguirre J.A., Korhonen L., Belluardo N., Lindholm D. Transgenic expression and activation of PGC-1alpha protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell Mol. Life Sci. 2012, 69:1153-1165.
34. Nasrin N., Kaushik V.K., Fortier E., Wall D., Pearson K.J., de Cabo R., Bordone L. JNK1 phosphorylates SIRT1 and promotes its enzymatic activity. PLoS One 2009, 4:e8414.
35. Niehaus W.G., Samuelsson B. Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation. Eur. J. Biochem. 1968, 6:126-130.
36. Pan-Montojo F., Reichmann H. Considerations on the role of environmental toxins in idiopathic Parkinson's disease pathophysiology. Transl. Neurodegener. 2014, 3:10.
37. Parkinson J. An essay on the shaking palsy. 1817. J.Neuropsychiatry Clin. Neurosci. 2002, 14:223-236. discussion 2.
38. Qin W., Yang T., Ho L., Zhao Z., Wang J., Chen L., Zhao W., Thiyagarajan M., MacGrogan D., Rodgers J.T., Puigserver P., Sadoshima J., Deng H., Pedrini S., Gandy S., Sauve A.A., Pasinetti G.M. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J.Biol. Chem. 2006, 281:21745-21754.
39. Rugbjerg K., Ritz B., Korbo L., Martinussen N., Olsen J.H. Risk of Parkinson's disease after hospital contact for head injury: population based case-control study. BMJ 2008, 337:a2494.
40. Salminen A., Kaarniranta K. SIRT1: regulation of longevity via autophagy. Cell Signal. 2009, 21:1356-1360.
41. Samii A., Nutt J.G., Ransom B.R. Parkinson's disease. Lancet 2004, 363:1783-1793.
42. Santos R., de Almodovar C.R., Bulteau A.L., Gomes C.M. Neurodegeneration, neurogenesis, and oxidative stress. Oxid. Med. Cell. Longev. 2013, 2013:730581.
43. Schaffer S.W., Azuma J., Mozaffari M. Role of antioxidant activity of taurine in diabetes. Can. J. Physiol. Pharmacol. 2009, 87:91-99.
44. Schieber M., Chandel N.S. ROS function in redox signaling and oxidative stress. Curr. Biol. 2014, 24:R453-R462.
45. Simon D.K., Lin M.T., Zheng L., Liu G.J., Ahn C.H., Kim L.M., Mauck W.M., Twu F., Beal M.F., Johns D.R. Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiol. Aging 2004, 25:71-81.
46. Spangenberg S., Hannerz H., Tuchsen F., Mikkelsen K.L. Anationwide population study of severe head injury and Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15:12-14.
47. Subramaniam S.R., Chesselet M.F. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Prog. Neurobiol. 2013, 106-107:17-32.
48. Tang B.L. Sirt1's complex roles in neuroprotection. Cell Mol. Neurobiol. 2009, 29:1093-1103.
49. Terpstra A.H., Woodward C.J., Sanchez-Muniz F.J. Improved techniques for the separation of serum lipoproteins by density gradient ultracentrifugation: visualization by prestaining and rapid separation of serum lipoproteins from small volumes of serum. Anal. Biochem. 1981, 111:149-157.
50. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., Nelson L.M. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 2003, 157:1015-1022.
51. van Wensen E., van Leeuwen R.B., van der Zaag-Loonen H.J., Masius-Olthof S., Bloem B.R. Benign paroxysmal positional vertigo in Parkinson's disease. Parkinsonism Relat. Disord. 2013, 19:1110-1112.
52. Vibert D., Sans A., Kompis M., Travo C., Muhlbauer R.C., Tschudi I., Boukhaddaoui H., Hausler R. Ultrastructural changes in otoconia of osteoporotic rats. Audiol. Neurootol. 2008, 13:293-301.
53. Walther L.E., Wenzel A., Buder J., Bloching M.B., Kniep R., Blodow A. Detection of human utricular otoconia degeneration in vital specimen and implications for benign paroxysmal positional vertigo. Eur. Arch. Otorhinolaryngol. 2013, 271:3133-3138.
54. Zappia J.J. Benign paroxysmal positional vertigo. Curr. Opin. Otolaryngol. Head Neck Surg. 2013, 21:480-486.